Management Strategies for Liver Fibrosis
Ann. hepatol
;
16(1): 48-56, Jan.-Feb. 2017. graf
Article
Dans Anglais
| LILACS
| ID: biblio-838085
ABSTRACT
Abstract Liver fibrosis resulting from chronic liver injury are major causes of morbidity and mortality worldwide. Among causes of hepatic fibrosis, viral infection is most common (hepatitis B and C). In addition, obesity rates worldwide have accelerated the risk of liver injury due to nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Also liver fibrosis is associated with the consumption of alcohol, or autoimmune hepatitis and chronic cholangiophaties. The response of hepatocytes to inflammation plays a decisive role in the physiopathology of hepatic fibrosis, which involves the recruitment of both pro- and anti-inflammatory cells such as monocytes and macrophages. As well as the production of other cytokines and chemokines, which increase the stimulus of hepatic stellate cells by activating proinflammatory cells. The aim of this review is to identify the therapeutic options available for the treatment of the liver fibrosis, enabling the prevention of progression when is detected in time.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Cirrhose du foie
/
Anti-inflammatoires
Type d'étude:
Etude d'étiologie
/
Étude pronostique
Limites du sujet:
Animaux
/
Humains
langue:
Anglais
Texte intégral:
Ann. hepatol
Thème du journal:
Gastroentérologie
Année:
2017
Type:
Article
Pays d'affiliation:
Mexique
Institution/Pays d'affiliation:
Medica Sur Clinic/MX
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS